No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis

Christopher Banse1
Aurélie Bisson-Vaivre1
Marie Kozyreff-Meurice1
Olivier Vittecoq1
Vincent Goëb2

1Rheumatology Department, Rouen University Hospital, Rouen, France; 2Rheumatology Department, Amiens University Hospital, Amiens, France

Objective: The use of anti-tumor necrosis factor (TNF) agents to treat joint manifestations of sarcoidosis has not been described. We evaluated the efficacy and safety of three such biologics in patients with these symptoms refractory to conventional therapy (nonsteroidal anti-inflammatory drugs, corticosteroids, and/or disease-modifying antirheumatic drugs).

Methods: This retrospective study, covering January 2001 to September 2011, examined clinical–biological parameters collected before anti-TNF treatment (age, sex, duration of disease evolution, drugs taken), and at introduction and under anti-TNF therapy (number of painful and swollen joints, visual analog scale score of global disease activity, disease-activity score of 28 joints with erythrocyte sedimentation rate or C-reactive protein, TNF-antagonist duration). At 3, 6, and 12 months, anti-TNF impact on joints and the therapeutic response according to European League Against Rheumatism criteria used for rheumatoid arthritis were assessed.

Results: Ten patients’ data were evaluated; some of them had received several anti-TNF agents (median [range] duration on each biotherapy was 10 [4–30] months), which enabled analysis of 19 prescriptions. The total duration of anti-TNF exposure was 17.6 patient-years, which was started a median of 3 (0.33–17) years after sarcoidosis diagnosis. The median numbers of painful and swollen joints were 1 (0–28) and 0 (0–9), respectively. Despite rapid efficacy, after 1 year of treatment, clinical (especially joint) and biological parameters were comparable to pretreatment, and only the corticosteroid dose was significantly lower (P=0.03). One case of mild skin toxicity was noted.

Conclusion: TNF antagonists allowed significant steroid sparing and were well tolerated, but do not seem to be effective against sarcoidosis joint involvement.

Keywords: sarcoidosis, anti-TNF, arthritis, adalimumab, etanercept, infliximab

Introduction

Conventional management of sarcoidosis with joint involvement (arthritis, arthralgias) relies on nonsteroidal anti-inflammatory drugs (NSAIDs) for the more moderate forms but sometimes requires corticosteroids.1 Corticoresistance is a sign of poor prognosis that necessitates the prescription of immunomodulators like methotrexate,2 and prognosis is even more dismal when extrapulmonary involvement is also present.3,4 Sarcoidosis is the consequence of an exaggerated monocyte-, macrophage- and T-lymphocyte-mediated immune response to still-unidentified antigens, leading to tumor necrosis factor (TNF) overproduction.5 This excessive synthesis plays a primordial role in the sustained formation of granuloma(s), the main sign of sarcoidosis.5 TNF inhibition may represent a new and relevant therapeutic approach to treat refractory sarcoidosis, notably when its clinical evolution is
invalidating and persistent, as TNF plays a preponderant role in sarcoidosis physiopathology. At present, the place of biologics, notably TNF antagonists, has not yet been clearly defined, and their use is currently off-label in sarcoidosis. To our knowledge, no study has specifically investigated the efficacy and safety of anti-TNF biotherapies in the context of joint manifestations of sarcoidosis. This study was undertaken to do so.

**Patients and methods**

**Patients**

This retrospective, observational study, covering January 2001 to September 2011, included all patients diagnosed with sarcoidosis meeting internationally recognized criteria and treated with TNF antagonist(s) due to articular involvement refractory to conventional therapy (NSAIDs, corticosteroids, and/or disease-modifying antirheumatic drugs [DMARDs]). In accordance with French guidelines, none of these patients had any contraindications to the use of these agents. Despite the fact that anti-TNF blockers are off-label in France to treat sarcoidosis, their use was decided after a multidisciplinary consensus. All the patients that we described here suffered from a severe clinical disease, required steroids, and/or suffered from methotrexate failure. Two patients with monoarthritis had already received several corticosteroid injections, but with no significant sustained effect. Informed written consent was obtained before anti-TNF prescription. This study conformed with French law and met the criteria of the local ethics committee.

Various clinical parameters were collected before starting treatment: age, sex, and disease duration since the first symptoms and until starting anti-TNF (infliximab, adalimumab or etanercept as first- and second-/third-line choices, respectively). While on TNF antagonist(s), duration of anti-TNF use and concomitant therapies (corticosteroids, methotrexate, NSAIDs) was recorded. To evaluate the clinical efficacy of these biologics, the following indicators were regularly noted during patient follow-up: the numbers of painful and swollen joints; the 28-joint disease-activity score (DAS28) to evaluate peripheral disease involvement, calculated with erythrocyte sedimentation rate (ESR/first hour) or C-reactive protein (CRP); DAS28 decrease of ≥1.2 points; the patient’s overall self-assessment of the disease using the visual analog scale (VAS) score; and biological markers (ESR/first hour and CRP concentration). Extra-articular involvement (pulmonary, ocular, neurological, cardiac, cutaneous, muscular) and adverse events or paradoxical side effects until anti-TNF discontinuation were recorded.

We used the composite DAS28 and European League Against Rheumatism (EULAR) score, usually applied to rheumatoid arthritis, as the principal response criterion to anti-TNF at 3, 6, and 12 months and at the end of treatment, and a ≥1.2-point DAS28 decline.

**Statistical analyses**

The before and after TNF-antagonist therapy medians and range of demographic, clinical, and biological characteristics were compared with Wilcoxon’s paired nonparametric test or McNemar’s test for quantitative or qualitative parameters, respectively. *P*<0.05 defined significance. Means ± standard deviation and 95% confidence intervals were calculated.

**Results**

**Demographic characteristics**

Ten patients (mean age 43 years [standard deviation 7.7], 60% males) were included (Table 1). Six of them had successively

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before</th>
<th>After</th>
<th><em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>43 (36–71)</td>
<td>40 (30–71)</td>
<td>0.90</td>
</tr>
<tr>
<td>Female:Male sex ratio</td>
<td>6:4</td>
<td>6:4</td>
<td>0.80</td>
</tr>
<tr>
<td>Disease evolution before anti-TNF, years</td>
<td>3 (0.33–17)</td>
<td>3 (0.33–17)</td>
<td>0.70</td>
</tr>
<tr>
<td>Months of anti-TNF therapy</td>
<td>10 (4–30)</td>
<td>10 (4–30)</td>
<td>0.70</td>
</tr>
<tr>
<td>Joint manifestation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Painful, n</td>
<td>1 (0–28)</td>
<td>0 (0–28)</td>
<td>0.40</td>
</tr>
<tr>
<td>Swollen, n</td>
<td>0 (0–9)</td>
<td>0 (0–9)</td>
<td>0.30</td>
</tr>
<tr>
<td>Global VAS score (0–100)</td>
<td>80 (50–100)</td>
<td>80 (30–90)</td>
<td>0.50</td>
</tr>
<tr>
<td>Extra-articular involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary, n</td>
<td>9</td>
<td>9</td>
<td>1.00</td>
</tr>
<tr>
<td>Ocular, n</td>
<td>2</td>
<td>2</td>
<td>1.00</td>
</tr>
<tr>
<td>Biological</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (mm/1st hour)</td>
<td>6 (1–13.6)</td>
<td>6 (1–13.6)</td>
<td>0.60</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>6.9 (1.8–6.05)</td>
<td>6.9 (1.8–6.05)</td>
<td>0.60</td>
</tr>
<tr>
<td>DAS28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ESR</td>
<td>3.57 (0.98–5.55)</td>
<td>3.07 (0.7–5.62)</td>
<td>0.50</td>
</tr>
<tr>
<td>With CRP</td>
<td>3.55 (2.58–6.05)</td>
<td>3.44 (1.8–6.05)</td>
<td>0.50</td>
</tr>
<tr>
<td>Concomitant treatments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIDs, n</td>
<td>12</td>
<td>10</td>
<td>0.40</td>
</tr>
<tr>
<td>Methotrexate, mg/week</td>
<td>0 (0–25)</td>
<td>0 (0–25)</td>
<td>0.40</td>
</tr>
<tr>
<td>Prednisone, mg/day</td>
<td>5 (0–40)</td>
<td>0 (0–10)</td>
<td>0.030</td>
</tr>
</tbody>
</table>

**Notes:** The before and after TNF-antagonist therapy medians (range) of demographic, clinical, and biological characteristics were compared with Wilcoxon’s paired nonparametric test or McNemar’s test for quantitative or qualitative parameters, respectively. *P*<0.05 defined significance. Results are expressed as medians (range) unless stated otherwise.

**Abbreviations:** TNF, tumor necrosis factor; VAS, visual analog scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS, disease-activity score; NSAIDs, nonsteroidal anti-inflammatory drugs.
received several anti-TNF biologics, enabling analysis of
19 prescriptions of TNF antagonists distributed as follows:
eight infliximab (5 mg/kg/6 weeks), eight adalimumab
(40 mg/2 weeks), and three etanercept (50 mg/1 week)
(Table 2). The overall median anti-TNF-treatment duration
was 10 (4–30) months, with respective mean infliximab,
adalimumab, and etanercept durations of 13.3, 11.8, and
6.3 months. The total exposure durations were 17.6 patient-
years, lasting, respectively, 7.08, 8.9, and 2.1 patient-years
for infliximab, adalimumab, and etanercept.

Before first anti-TNF therapy
Among the ten patients, five had arthralgias without
swelling and five had arthritis, including two mono-, one
oligo-, and two polyarthritis. Three patients also satisfied
the European Spondyloarthropathy Study Group (ESSG)
classification criteria.11 None of the patients fulfilled the
American College of Rheumatology/EULAR criteria of
rheumatoid arthritis. Their median (range) values for all the
studied parameters are reported in Table 1. No biological
inflammatory syndromes (CRP, ESR) were observed
before initiation of TNF blockers. Before the beginning of
TNF blockers, according to their DAS28-CRP scores, six
patients had low articular involvement (DAS28 ≤3.2), two
moderate (3.2 < DAS28 ≤5.1), and two active involvement
(DAS28 >5.1). Extra-articular involvement was distributed
as follows: seven pulmonary, two ocular, one cardiac, and
two muscular (Table 2).

The median interval between sarcoidosis diagnosis and
start of the first biotherapy was 3 (0–17) years. Five patients
did not receive methotrexate during the initiation of the TNFα
inhibitor, but had received methotrexate in the previous
months. The methotrexate was stopped because of liver
cytolysis. One patient also suffered from renal impairment
that led to methotrexate discontinuation. Nine patients
received combined methotrexate and TNF antagonist, and
ten received the biologic alone. Two-thirds of the patients
took NSAIDs before starting the anti-TNF.

Under TNF antagonists
No significant anti-TNF impact on articular manifestations
(numbers of painful and swollen joints, DAS28 with ESR
or CRP, global VAS score), extra-articular involvement
(pulmonary, ocular, cardiac, muscular), or biological
indicators of inflammatory syndrome were observed
(Table 1).

Considering all 19 anti-TNF prescriptions and the
EULAR score of clinical response (9), nine achieved
satisfactory (DAS28 ≤3.2) and five moderate responses
(DAS28 >3.2–≤5.1), whereas five showed no change
(DAS28 >5.1). At 6 months, five patients had DAS28
declines >1.2. However, anti-TNF effectiveness, evaluated
using the EULAR score after 3, 6, and 12 months, showed
initial moderate or satisfactory efficacy (14/19, 73.7%) at
3 months, followed by progressive therapeutic escapes
leading to 13 treatment discontinuations because of
insufficient responses at 1 year (Figure 1).

Moreover, TNF antagonists had no significant impact
on methotrexate or NSAID use. In contrast, they allowed
significant corticosteroid sparing, according to the number
of patients (14 before and nine after), and almost halved the
mean prednisone dose (6.3 versus 3.2 mg/day).

Among the 19 anti-TNF prescriptions, three engendered
adverse events: two mild infections (vaginal mycosis and
bronchitis not requiring hospitalization) and one toxiderma
that resolved after treatment withdrawal. No cancer or severe
infection occurred under treatment.

No radiological evidence for presence of noncaseating
granulomas before or during anti-TNF treatment was
observed.

Discussion
Only a small percentage of sarcoidosis patients have
persistent joint involvement (15%–25%),12 eg, incapacitating
polyarthralgia or mono-/oligoarthritis that requires DMARDs,
and the risk of developing or aggravating pulmonary fibrosis
is higher when extrapulmonary involvement is uncontrolled.13
Our observations indicate that the different TNF antagonists
achieved rapid attenuation of sarcoidosis joint symptoms
during the first 3 months, but failed to control any of the
studied parameters (number of painful and swollen joints,
global VAS, DAS28, and EULAR criteria) thereafter. This
rapid regression of manifestations might be explained by a
placebo effect or real efficacy that faded over time due to the
immunogenicity of the anti-TNF antibodies predominantly
prescribed to our study patients.

Pertinently, TNF-antagonist use did obtain significant,
albeit moderate, corticosteroid sparing. Moreover, their
safety seems good, because no severe adverse events
occurred under treatment.

Two double-blinded randomized controlled trials versus
placebo evaluated infliximab efficacy against pulmonary
sarcoidosis. Rossman et al14 demonstrated improved
lung vital capacity under this biologic, but did not assess
joint involvement, whereas Hostettler et al’s investigation
completing the former showed infliximab efficacy against
Table 2 Distribution of the 19 prescriptions of TNF blockers among the ten patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>Sex/age</th>
<th>Sarcoïdosis involvement</th>
<th>Anti-TNF (prescription in months)</th>
<th>Prednisone (mg/day)</th>
<th>MTX (mg/week)</th>
<th>DAS28 CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Woman (57)</td>
<td>Monoarthritis Pulmonary Cardiac Muscular</td>
<td>Infliximab (30 months) Before 5 0 3.15 After 10 15 5.54 Adalimumab (5 months) Before 10 15 5.54 After 10 0 5.61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Woman (43)</td>
<td>Arthralgias –</td>
<td>Adalimumab (8 months) Before 5 0 5.18 After 0 0 3.44 Etanercept (7 months) Before 0 0 3.61 After 5 0 2.83 Infliximab (10 months) Before 5 0 2.83 After 0 0 2.95</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Woman (61)</td>
<td>Arthralgias Pulmonary Cutaneous Muscular</td>
<td>Infliximab (6 months) Before 12 25 3.55 After 3 12.5 6.05 Adalimumab (12 months) Before 3 12.5 6.05 After 0 0 2.55</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Man (38)</td>
<td>Polyarthritis Pulmonary</td>
<td>Adalimumab (18 months) Before 0 0 2.72 After 0 0 2.13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Woman (39)</td>
<td>Arthralgias Pulmonary</td>
<td>Infliximab (15 months) Before 0 0 5.24 After 0 20 5.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Man (36)</td>
<td>Monoarthritis Pulmonary</td>
<td>Adalimumab (7 months) Before 5 15 2.59 After 5 17.5 2.59</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Woman (43)</td>
<td>Oligoarthritis Pulmonary Ocular</td>
<td>Adalimumab (7 months) Before 5 0 4.9 After 0 0 5.83 Etanercept (8 months) Before 5 0 5.83 After 5 0 2.83 Infliximab (10 months) Before 5 10 2.83 After 0 0 5.26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Woman (71)</td>
<td>Arthralgias Pulmonary Ocular</td>
<td>Infliximab (16 months) Before 20 25 2.58 After 10 27.5 4.91 Adalimumab (16 months) Before 10 27.5 4.91 After 5 20 1.91</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Man (39)</td>
<td>Polyarthritis Cutaneous</td>
<td>Infliximab (11 months) Before 20 7.5 2.89 After 0 7.5 4.3 Etanercept (4 months) Before 0 7.5 3.71 After 0 7.5 3.45 Adalimumab (12 months) Before 0 7.5 3.45 After 0 0 1.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Man (61)</td>
<td>Arthralgia –</td>
<td>Infliximab (9 months) Before 10 0 2.86</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: TNF, tumor necrosis factor; MTX, methotrexate; DAS, disease-activity score; CRP, C-reactive protein.
corticosteroid-resistant sarcoidosis, especially for patients with extrapulmonary disease. Indeed, six of the eleven patients with extrapulmonary involvement were in remission on biotherapy. Jounieaux et al retrospectively examined infliximab efficacy against pulmonary and/or systemic (≥ four organs involved) sarcoidosis and found a beneficial response at 13±12 months for 62% of the patients for all organs combined, with 65% efficacy for lung, 67% for skin, and 50% for central nervous system involvement. However, the infliximab effect was not significant for lung involvement. The results of those studies did not consider joint changes under that TNF antagonist.

Judson et al conducted the only trial to evaluate sarcoidosis joint manifestations under infliximab. That prospective randomized controlled versus placebo study on 138 patients assessed biologic efficacy against extrapulmonary involvement of sarcoidosis. No satisfactory impact on joint disease was observed at 24 and 48 weeks, even though significant attenuation of involvement for all organs combined was observed at 28 weeks. A weakness of that study was that 20 patients with joint manifestations of sarcoidosis were evaluated with a subjective judgment criterion (the physician’s evaluation). Thus, the effectiveness of TNF-blocking agents in sarcoidosis have not been demonstrated, even in patients with extra pulmonary disease. The results of our study are therefore consistent with the conclusion of a recent review by Maneiro et al that stated that there was insufficient evidence to ensure the efficacy of TNF antagonists in sarcoidosis.

Finally, infliximab did not show evidence of its efficiency in articular manifestations of sarcoidosis. This monoclonal antibody directed against TNF may not be active in joint granulomas. The small number of patients in our observation may explain why the DAS28 worsened after infliximab.

Controlled-trial results have demonstrated etanercept inefficacy against respiratory and chronic ocular sarcoidosis involvement. However, those studies did not address patients’ rheumatological manifestations before and after biotherapy administration. In addition, some monoclonal anti-TNF agents induced sarcoidosis, as we previously described. Concerning our three etanercept prescriptions, they were second-/third-line treatments given after monoclonal antibody failure to patients whose clinical pictures were intermediary between sarcoidosis and ankylosing spondylarthritis, according to ESSG criteria. A subanalysis of the different parameters before and after starting anti-TNF identified no significant differences. The efficacies of the soluble receptor and the monoclonal anti-TNF antibodies (infliximab and adalimumab) could not be compared herein because of the small numbers of patients included.

Corticosteroid sparing is essential in chronic pathologies to contain the occurrence of iatrogenic complications, like Cushing’s syndrome, diabetes, or steroid-induced osteoporosis. Jounieaux et al observed corticosteroid sparing, estimated at 2.8 mg/day, close to that observed herein (3.1 mg/day). Baughman et al did not find a decline of the
corticoid dose (topical or systemic) after adding etanercept to the regimen. Our patients’ methotrexate and NSAID use also diminished, but not significantly, by 8.8% and 8.3%, respectively.

Our patients’ mild inflammatory syndromes also decreased nonsignificantly after the adjunction of anti-TNF, with CRP and ESR being 19.8% and 12.6% lower (P=0.2 and 0.65), respectively.

The small sample size of patients did not allow us to study the dose-dependent response to TNF inhibition in sarcoidosis, since all but one of the patients received a dose of 5 mg/kg of infliximab (only one patient began the infliximab treatment with a 3 mg/kg starting dose that was enhanced to 5 mg/kg after 3 months).

We observed good safety of the different biotherapies, with three side effects for a total duration of exposure of 17.6 patient-years, with mild toxaemia the only notable toxicity under infliximab. In contrast, Jounieux et al reported that 13 of 31 patients developed adverse events, seven severe, sometimes requiring infliximab withdrawal. This difference is probably attributable to the different population they studied: longer-standing (9 years) and systemic (a mean of four organs involved) sarcoidosis. In their multicenter study, Rossman et al evaluated the contribution of infliximab against corticoresistant pulmonary sarcoidosis: four of 19 patients had severe disease. In a study evaluating etanercept efficacy against pulmonary sarcoidosis, two of the 17 patients included developed severe side effects (lymphoma and plasmacytoma).

One of the limits of our study was the small number of patients included retrospectively. However, this population had sarcoidosis characterized by quasi-exclusive joint involvement, sometimes diagnosed with sarcoidosis and ankylosing spondylarthritis overlap syndrome. This association has already been described. Inflammatory joint pain has already been described as the most frequent articular involvement of sarcoidosis. We assessed disease activity with the composite EULAR score usually used for rheumatoid arthritis, because no validated score is available to evaluate the evolution of the inflammatory joint activity of sarcoidosis under treatment. Moreover, calculating a composite index (DAS28) in a group of patients with low ESR and CRP and low frequency of clinically overt arthritis is probably not the most relevant method of evaluation.

To our knowledge, this is the only study to address specifically the efficacy and safety of TNF antagonists (infliximab, adalimumab, and etanercept) in the context of sarcoidosis joint involvement. However, to assess objectively anti-TNF efficacy for this rare indication, a prospective randomized controlled trial on a larger population will be necessary.

**Disclosure**

The authors have no conflicts of interest to declare.

**References**


